The paper describes a new class of human (h) A3 adenosine receptor antagonists, the 2-arylpyrido[2,3-e]- 1,2,4-triazolo[4,3-a]pyrazin-1-one derivatives (PTP), either 4-oxo (1-6, series A) or 4-amino-substituted (7-20, series B). In both series A and B, substituents able to act as hydrogen bond acceptors (OMe, OH, F, COOEt) were inserted on the 2-phenyl ring. In series B, cycloalkyl and acyl residues were introduced on the 4-amino group. Some of the new derivatives showed high hA3 AR affinities (Ki < 50 nM) and selectivities vs both hA1 and hA2A receptors. The selected 4-benzoylamino-2-(4-methoxyphenyl)pyrido[2,3-e]-1,2,4- triazolo[4,3-a]pyrazin-1-one (18), tested in an in vitro rat model of cerebral ischemia, proved to be effective in preventing the failure of synaptic activity induced by oxygen and glucose deprivation in the hippocampus. Molecular docking of this new class of hA3 AR antagonists was carried out to depict their hypothetical binding mode to our refined model of hA3 receptor.

Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand-Receptor Modeling Studies / V. Colotta; O. Lenzi; D. Catarzi; F. Varano; G. Filacchioni; C. Martini; L. Trincavelli; O. Ciampi; A. M. Pugliese; C. Traini; F. Pedata; E. Morizzo; S. Moro. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - STAMPA. - 52:(2009), pp. 2407-2419. [10.1021/jm8014876]

Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand-Receptor Modeling Studies.

COLOTTA, VITTORIA;CATARZI, DANIELA;VARANO, FLAVIA;FILACCHIONI, GUIDO;PUGLIESE, ANNA MARIA;TRAINI, CHIARA;PEDATA, FELICITA;
2009

Abstract

The paper describes a new class of human (h) A3 adenosine receptor antagonists, the 2-arylpyrido[2,3-e]- 1,2,4-triazolo[4,3-a]pyrazin-1-one derivatives (PTP), either 4-oxo (1-6, series A) or 4-amino-substituted (7-20, series B). In both series A and B, substituents able to act as hydrogen bond acceptors (OMe, OH, F, COOEt) were inserted on the 2-phenyl ring. In series B, cycloalkyl and acyl residues were introduced on the 4-amino group. Some of the new derivatives showed high hA3 AR affinities (Ki < 50 nM) and selectivities vs both hA1 and hA2A receptors. The selected 4-benzoylamino-2-(4-methoxyphenyl)pyrido[2,3-e]-1,2,4- triazolo[4,3-a]pyrazin-1-one (18), tested in an in vitro rat model of cerebral ischemia, proved to be effective in preventing the failure of synaptic activity induced by oxygen and glucose deprivation in the hippocampus. Molecular docking of this new class of hA3 AR antagonists was carried out to depict their hypothetical binding mode to our refined model of hA3 receptor.
2009
52
2407
2419
V. Colotta; O. Lenzi; D. Catarzi; F. Varano; G. Filacchioni; C. Martini; L. Trincavelli; O. Ciampi; A. M. Pugliese; C. Traini; F. Pedata; E. Morizzo; S. Moro
File in questo prodotto:
File Dimensione Formato  
colotta,2009,52,2407.pdf

Accesso chiuso

Tipologia: Altro
Licenza: Tutti i diritti riservati
Dimensione 846.5 kB
Formato Adobe PDF
846.5 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/369472
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 35
social impact